Revvity Unveils Innovative Cancer Research Solutions at AACR Annual Meeting 2025
Revvity is set to showcase a range of cutting-edge cancer research solutions at the AACR Annual Meeting 2025, held in Chicago from April 25-30. The company will present its VivoJect Image-Guided Injection System, which allows for real-time imaging and precise operation for researchers. Paired with the Vegatm automated preclinical ultrasound system, this system increases throughput compared to traditional techniques. Revvity's diverse portfolio will also be on display, featuring the PhenoVuetm DNA Damage Response Staining Kit, Harmonytm 5.3 and Phenologic.AItm high-content image analysis software, and over 120 cell line-derived oncology reference standards from the Mimixtm portfolio.
Key Takeaways:
- Revvity will unveil the VivoJect Image-Guided Injection System, paired with the Vegatm automated preclinical ultrasound system, at the AACR Annual Meeting 2025.
- The VivoJect system enables real-time imaging and precise operation, increasing throughput compared to traditional techniques.
- Revvity's portfolio features the PhenoVuetm DNA Damage Response Staining Kit, Harmonytm 5.3, and Phenologic.AItm high-content image analysis software.
- The company will showcase over 120 cell line-derived oncology reference standards from the Mimixtm portfolio.
- BioLegend's reagent innovations will also be on display, including the TotalSeqtm PhenoCyte, TotalSeq-A, and -C Universal Cocktails, v2.0.
- Revvity's solutions are designed to support researchers across various stages of their research, from early discovery to translational studies.
- The company's booth will feature exhibits on cell analysis in 3D, AI, immunoassays, in vivo imaging, and genomic solutions.
Sources:
- Revvity news release
- AACR Annual Meeting 2025
- BioLegend's reagent innovations